Abstract
Gene-engineered dendritic cells (DC) are being tested in cancer immunotherapy. DC are the best equipped antigen-presenting cells (APC) to overcome tolerance / ignorance to self antigens presented by cancer cells. Genetic immunotherapy with DC engineered to express tumor antigens has the potential advantages of endogenous epitope presentation by both major histocompatibility complex (MHC) class I and II molecules. DC can also be gene-modified to express immunostimulatory molecules that further enhance their antigen-presenting function. Review of the literature provided 52 manuscripts where gene-modified DC were being tested in murine models of immunotherapy for cancer. Review of the antitumor effects of gene-modified DC in these preclinical studies provides valuable information on the optimal methods of gene transfer into DC, the schedule of administration, the route, dose and the underlying immunological mechanisms of the antitumor effects. These data may help in the translation of this promising approach to the clinic.
Keywords: Cancer Immunotherapy, Gene-Modified Dendritic Cells, immunostimulatory molecules, proteasome complex, Viral Vector Transduction, Takayama
Related Books
Applied Biomathematics for Nucleic Acid Chemistry and Protein Folding: Quantitative Simulations
Industrial Applications of Soil Microbes
Molecular and Physiological Insights into Plant Stress Tolerance and Applications in Agriculture
Systems Biology, Bioinformatics and Livestock Science
Advances in Legume Research: Physiological Responses and Genetic Improvement for Stress Resistance
Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach
Future Farming: Advancing Agriculture with Artificial Intelligence
Genome Size and Genetic Homogeneity of Regenerated Plants: Methods and Applications
The Drone Honey Bee
Fungal Lipid Biochemistry
17